arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Humacyte, Inc.

HUMA
$0.56 ▼ -0.02 (-3.35%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Humacyte, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $131.1M
Dividend Yield
Revenue Growth 34.9%
Op. Margin
ROIC -31.6%
FCF / Share $-0.09
Trailing P/E
Price / Book 5.0x
FCF Yield
Debt / Equity 1.16
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$406.00K
↑ +34.9%
Net Income Profit after all expenses
$-17.62M
— 0.0%
FCF / Share Free cash flow per share
$-0.09
↑ +25.9%
Long-Term Debt Long-term obligations
$36.32M
↑ +1.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health
2
Cash Quality
90

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters